Dec 6 (Reuters) - BIOAGE Labs Inc BIOA.O:
BIOAGE LABS ANNOUNCES DISCONTINUATION OF STRIDES PHASE 2 CLINICAL TRIAL EVALUATING AZELAPRAG IN COMBINATION WITH TIRZEPATIDE FOR THE TREATMENT OF OBESITY
BIOAGE LABS INC - NO TRANSAMINASE ELEVATIONS IN TIRZEPATIDE ONLY GROUP
BIOAGE LABS INC - DECISION FOLLOWS OBSERVATIONS OF LIVER TRANSAMINITIS WITHOUT CLINICALLY SIGNIFICANT SYMPTOMS IN SOME SUBJECTS ON AZELAPRAG
BIOAGE LABS INC - DOSING DISCONTINUED, NO ADDITIONAL SUBJECTS TO BE ENROLLED
Source text: ID:nGNX5JjjwD
Further company coverage: BIOA.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。